Ingredient profile
acrylamide
Raters disagreeCAS 79-06-1
At least one of our safety lists speaks to this ingredient. Also written as Acrylamide, ACRYLAMIDE.
Raters don't agree. Here's where each one stands
Safe
Greenlens Ingredient Scan
Independent
Greenlens Precautionary Screen
Independent
Greenlens Tolerance Screen
Independent
Caution
US NTP Report on Carcinogens
Government
Concern
Health Canada Ingredient Hotlist
Government
IARC Monographs
Government
EU Harmonised Classification (CLP Annex VI)
Government
Where each list lands
Funding shown- Concern
Health Canada Ingredient Hotlist
Government
Free acrylamide monomer is prohibited in cosmetics (residual limits govern its polymers elsewhere). (Health Canada Cosmetic Ingredient Hotlist)
- Caution
US NTP Report on Carcinogens
Government
Acrylamide, a residual monomer in some polyacrylamide thickeners/film-formers, is reasonably anticipated to be a human carcinogen. (US NTP Report on Carcinogens (15th ed.))
- Concern
Also screened — not on these lists
- California Proposition 65
- ANSES Endocrine Disruptors
- EU Microplastics Restriction
Where regulators stand
Shown side by side, never combinedEach jurisdiction is reported on its own terms, from its own official lists. Where they disagree, that disagreement is the finding. Absence from a list is never a safety claim.
European Union
BannedProhibited as a cosmetic ingredient in this jurisdiction.
- European Commission · EU Cosmetics Regulation Annex II (prohibited)Listed in Annex II of the EU Cosmetics Regulation (ref 681) — prohibited as an ingredient in cosmetic products.
- ECHA (EU CLP Regulation) · EU CLP Regulation Annex VI, Table 3 (harmonised classification, ECHA export): Carc. 1B, Muta. 1B, Repr. 2, Skin Sens. 1Carries an EU harmonised classification (Carc. 1B, Muta. 1B, Repr. 2, Skin Sens. 1) — a definite (category 1A/1B) carcinogen, mutagen or reproductive toxicant under CLP Annex VI, index 616-003-00-0. A hazard classification, not proof of harm at the level used.
Canada
BannedProhibited as a cosmetic ingredient in this jurisdiction.
Notes
- EU harmonised CMR (cat. 1)
- Health Canada Hotlist — prohibited
- NTP anticipated carcinogen
- IARC probable carcinogen (Group 2A)
